Evaluation of Candida peritonitis with underlying peritoneal fibrosis and efficacy of micafungin in murine models of intra-abdominal candidiasis

[1]  Pengfei Guo,et al.  A meta-analysis of randomized controlled trials , 2019, Medicine.

[2]  C. Clancy,et al.  Non-Culture Diagnostics for Invasive Candidiasis: Promise and Unintended Consequences , 2018, Journal of fungi.

[3]  Annalisa Capobianco,et al.  The peritoneum: healing, immunity, and diseases , 2017, The Journal of pathology.

[4]  M. H. Lee,et al.  Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model , 2017, Open Forum Infectious Diseases.

[5]  Craig A. Poland,et al.  Targeting lysyl oxidase reduces peritoneal fibrosis , 2017, PloS one.

[6]  M. H. Lee,et al.  Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model , 2017, Antimicrobial Agents and Chemotherapy.

[7]  Jung‐Chung Lin,et al.  Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: A meta-analysis of randomized controlled trials , 2017, PloS one.

[8]  Wen-juan Wang,et al.  Blocking TGF-β1 by P17 peptides attenuates gastric cancer cell induced peritoneal fibrosis and prevents peritoneal dissemination in vitro and in vivo. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[9]  David W. Johnson,et al.  ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment , 2016, Peritoneal Dialysis International.

[10]  S. Park,et al.  Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment , 2016, PloS one.

[11]  T. Nishino,et al.  Chondroitin sulfate prevents peritoneal fibrosis in mice by suppressing NF-κB activation , 2016, Medical Molecular Morphology.

[12]  J. Sobel,et al.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  D. Andes,et al.  Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice , 2015, Antimicrobial Agents and Chemotherapy.

[14]  M. Antonelli,et al.  A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality , 2015, Intensive Care Medicine.

[15]  C. Clancy,et al.  Abdominal Candidiasis Is a Hidden Reservoir of Echinocandin Resistance , 2014, Antimicrobial Agents and Chemotherapy.

[16]  Ronald N. Jones,et al.  Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. , 2014, International journal of antimicrobial agents.

[17]  M. Nagarkatti,et al.  Role of cytokines as a double-edged sword in sepsis. , 2013, In vivo.

[18]  A. Shorr,et al.  A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts , 2013, Intensive Care Medicine.

[19]  Y. Tabata,et al.  HSP47 siRNA conjugated with cationized gelatin microspheres suppresses peritoneal fibrosis in mice. , 2012, Acta biomaterialia.

[20]  Amit X Garg,et al.  Global trends in rates of peritoneal dialysis. , 2012, Journal of the American Society of Nephrology : JASN.

[21]  David W. Johnson,et al.  Relapsing and recurrent peritoneal dialysis-associated peritonitis: a multicenter registry study. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  O. Lortholary,et al.  A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[23]  Y. Tomino,et al.  Quantitative evaluation and assessment of peritoneal morphologic changes in peritoneal dialysis patients. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  C. Venetis,et al.  Prevention of intra-peritoneal adhesions in gynaecological surgery: theory and evidence. , 2010, Reproductive biomedicine online.

[25]  O. Devuyst,et al.  The pathophysiology of the peritoneal membrane. , 2010, Journal of the American Society of Nephrology : JASN.

[26]  E. Anaissie,et al.  Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  M. Pfaller,et al.  In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model , 2008, Antimicrobial Agents and Chemotherapy.

[28]  A. Kimura,et al.  In Vitro and In Vivo Antifungal Activities of T-2307, a Novel Arylamidine , 2008, Antimicrobial Agents and Chemotherapy.

[29]  M. Pfaller,et al.  Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.

[30]  J. Keirns,et al.  Steady-State Pharmacokinetics of Micafungin and Voriconazole after Separate and Concomitant Dosing in Healthy Adults , 2006, Antimicrobial Agents and Chemotherapy.

[31]  H. Iwasaki,et al.  Candin family antifungal agent micafungin (FK463) modulates the inflammatory cytokine production stimulated by lipopolysaccharide in THP-1 cells. , 2006, Translational research : the journal of laboratory and clinical medicine.

[32]  J. Sobel,et al.  Micafungin: a new echinocandin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  Simona Gioberge,et al.  ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  S. Swan,et al.  Pharmacokinetics of Micafungin in Healthy Volunteers, Volunteers With Moderate Liver Disease, and Volunteers With Renal Dysfunction , 2005, Journal of clinical pharmacology.

[35]  T. Nishino,et al.  TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. , 2004, Kidney international.

[36]  T. Koji,et al.  Enhanced Expression of Heat Shock Protein 47 in Rat Model of Peritoneal Fibrosis , 2003, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[37]  J. Jekel,et al.  Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  Geraint T. Williams,et al.  Morphologic changes in the peritoneal membrane of patients with renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[39]  Koji Kawabata,et al.  In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi , 2000, Antimicrobial Agents and Chemotherapy.

[40]  A. Kliger,et al.  Fungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[41]  S. Davies,et al.  Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[42]  T. Calandra,et al.  Changes in the epidemiological landscape of invasive candidiasis , 2018, The Journal of antimicrobial chemotherapy.

[43]  L. Miao,et al.  A review of rodent models of peritoneal dialysis and its complications , 2014, International Urology and Nephrology.

[44]  H. Flynn,et al.  Update on the prevention and treatment of , 2014 .

[45]  Francisco Ferreira,et al.  Theory and Evidence , 2009 .